Reports

Drug name	NICE TAs	Comments
Indermil tissue adhesive
Indometacin (Indocid PDA)
Infliximab	TA329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab injection (Remicade®, Inflectra®, Remsima®)	TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA143 - Adalimumab , etanercept and infliximab for ankylosing spondylitis TA130 - Adalimumab , etanercept and infliximab for the treatment of rheumatoid arthritis TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Infliximab#13.5	TA134 - Infliximab for the treatment of adults with psoriasis
Inotuzumab ozogamicin (Besponsa®)	TA541 - Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Insulin degludec 100 units/ml (Tresiba®)#red		Amber for type 1 diabetes- specialist initiation. RICaD. Red for Type 2 diabetes.
Interferon Alfa-2A injection
Interferon Alfa-2B pen	TA75 - Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C TA200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Interferon beta	TA200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports